The Merck KGaA MET kinase inhibitor, tepotinib, was approved earlier this year for METex14 positive NSCLC patients, and is administered once-daily in contrast to capmatinib, which was approved in 2020. Both molecules were approved based on small numbers of patients (tepotinib pivotal trial: NCT02864992) due to the significance of the [...]
< 1 minute read
Dec. 20, 2021
Tepotinib: a KGaA MET Kinase Inhibitor
tepotinib
oral MET kinase inhibitor approved for clinical use in NSCLC internal HTS and SBDD Clinical Cancer Research Merck KGaA